Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy.

Copenhagen University Hospital, Copenhagen, Denmark.

Survival: monthsCountry:Denmark
Toxiciy Grade:5City/State/Province:Copenhagen
Treatments:ChemotherapyHospital:Copenhagen University Hospital
Drugs:Journal:Link
Date:Oct 2010

Description:

Patients:
This study involved 79 women with recurrent epithelial ovarian cancer with a median age of 59 years (range 31-77).

Treatment:
Patients were treated with two chemotherapy agents, gemcitabine and pegylated liposomal doxorubicin (PLD), which stop cancer cell growth by inhibiting cell division.

Toxicities:
There was one treatment-related death reported in this study, which was attributed to lung inflammation. Other grade 3 or 4 toxicities reported were febrile neutropenia, hand-foot skin reactions, mucositis (mouth sores), and nausea.

Results:
The median overall survival in this study was 12.5 months and median progression-free survival was 6.4 months.

Support:
This study was partially supported by Eli Lilly, makers of gemcitabine (brand name Gemzar), and Schering Plough.

Correspondence: Dr. Mansoor R. Mirza; email: [email protected]



Back